Refractory IGκ/ IRF4-positive DLBCL with CDKN2A/ 2B deletion.

Authors :: Chonabayashi, Kazuhisa
Tamori, Shigeki
Taniwaki, Masafumi
Fujita, Haruyuki
Shimazu, Yayoi
Matsui, Yusuke
Hishizawa, Masakatsu
Usami, Kazumasa
Takaori-Kondo, Akifumi
Source :: Annals of Hematology. May2014, Vol. 93 Issue 5, p893-894. 2p.
Publication Year :: 2014
Abstract: A letter to the editor is presented which discusses a case study of a 52 year old man who was suffering from severe anemia and mentions that the deletion of cyclin dependent kinase inhibitor (CDKN) 2A/2B for diffuse large B cell lymphoma (DLBCL) has the therapeutic characteristics.